Taiho Pharmaceutical to Acquire Araris Biotech for ~$1.1B
Shots:
- Taiho Pharmaceutical has entered into a definitive agreement to acquire Araris Biotech following a 2023 research collaboration between them; closing expected in H1'25
- As per the deal, Araris Biotech will receive $400M upfront at closing & ~$740M in milestones, becoming a wholly owned subsidiary of Taiho Pharmaceutical, while continuing its operations in Zurich, Switzerland
- Acquisition will strengthen Taiho’s ADC portfolio with Araris’s AraLinQ platform & 3 preclinical assets set for clinical development in 2025-2026. Taiho also aims to advance its oncology pipeline by integrating its Cysteinomix drug discovery platform with the AraLinQ
Ref: Taiho | Image: Araris
Related News:- Endo & Mallinckrodt Pharmaceuticals to Form a Combine Entity with $6.7B Cash-and-Stock
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
